- Home
- XFOR vs FLUX Comparison
XFOR vs FLUX Comparison
Compare XFOR & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- FLUX
- Stock Information
- Founded
- XFOR 2014
- FLUX N/A
- Country
- XFOR United States
- FLUX United States
- Employees
- XFOR N/A
- FLUX N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- FLUX Industrial Machinery/Components
- Sector
- XFOR Health Care
- FLUX Miscellaneous
- Exchange
- XFOR Nasdaq
- FLUX Nasdaq
- Market Cap
- XFOR 84.3M
- FLUX 98.5M
- IPO Year
- XFOR N/A
- FLUX N/A
- Fundamental
- Price
- XFOR $3.81
- FLUX $4.34
- Analyst Decision
- XFOR Strong Buy
- FLUX Strong Buy
- Analyst Count
- XFOR 3
- FLUX 2
- Target Price
- XFOR $34.17
- FLUX $6.00
- AVG Volume (30 Days)
- XFOR 1.4M
- FLUX 762.0K
- Earning Date
- XFOR 11-12-2025
- FLUX 09-16-2025
- Dividend Yield
- XFOR N/A
- FLUX N/A
- EPS Growth
- XFOR N/A
- FLUX N/A
- EPS
- XFOR N/A
- FLUX N/A
- Revenue
- XFOR $32,774,000.00
- FLUX $66,434,000.00
- Revenue This Year
- XFOR $1,307.51
- FLUX $8.23
- Revenue Next Year
- XFOR N/A
- FLUX $24.72
- P/E Ratio
- XFOR N/A
- FLUX N/A
- Revenue Growth
- XFOR 5721.31
- FLUX 9.22
- 52 Week Low
- XFOR $1.35
- FLUX $1.15
- 52 Week High
- XFOR $26.83
- FLUX $7.55
- Technical
- Relative Strength Index (RSI)
- XFOR 62.18
- FLUX 55.19
- Support Level
- XFOR $2.96
- FLUX $5.44
- Resistance Level
- XFOR $4.54
- FLUX $7.55
- Average True Range (ATR)
- XFOR 0.27
- FLUX 0.93
- MACD
- XFOR 0.07
- FLUX -0.12
- Stochastic Oscillator
- XFOR 55.75
- FLUX 20.08
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.